Physician profile
Carlos E Morales
NPI 1831211705
$14,114.83
in general payments reported to CMS, 2019-2025
18 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $120 · 2021: $10K · 2022: $506 · 2023: $1,408 · 2024: $892 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,909.84 | 2021-2025 | Corevalve Evolut R, Abre, Claria Mri Quad Crt-D Surescan |
| Abbott Laboratories | $399.74 | 2019-2025 | Dragonfly Opstar, Freestyle Libre 3 |
| Abiomed | $270.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $256.43 | 2023-2024 | Camzyos |
| Stryker Corporation | $170.50 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $154.66 | 2024 | Avvigo Guidance System |
| Philips North America LLC | $120.58 | 2022 | |
| Dova Pharmaceuticals | $113.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.67 | 2020 | |
| W. L. Gore & Associates, INC. | $103.89 | 2019 | |
| Cardiva Medical, INC. | $90.51 | 2022 | |
| Cardiovascular Systems INC. | $82.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $79.11 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.61 | 2019 | |
| Siemens Medical Solutions USA, INC. | $60.83 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.85 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $49.23 | 2021 | |
| Terumo Medical Corporation | $20.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.